ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (SMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00873249
Recruitment Status : Completed
First Posted : April 1, 2009
Last Update Posted : March 24, 2010
Sponsor:
Information provided by:
AstraZeneca

March 31, 2009
April 1, 2009
March 24, 2010
April 2009
March 2010   (Final data collection date for primary outcome measure)
Morisky Green Questionnaire [ Time Frame: baseline, at months 3 and 6 ]
Same as current
Complete list of historical versions of study NCT00873249 on ClinicalTrials.gov Archive Site
  • Clinical Global Impression- Schizophrenia (CGI-SCH) [ Time Frame: baseline, at months 3 and 6 ]
  • Register of Adherence to Treatment (RAT) [ Time Frame: baseline, at months 3 and 6 ]
Same as current
Not Provided
Not Provided
 
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Stabilized outpatients with a diagnosis of schizophrenia
Schizophrenia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
339
360
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients older than 18 years
  • With a diagnosis of schizophrenia (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under oral antipsychotic monotherapy

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Suicide risk
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00873249
NIS-NES-DUM-2007/3
No
Not Provided
Not Provided
Teresa Diez, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Not Provided
AstraZeneca
March 2010